Search results

Quoting a post about another immune system resource, the book 'Immune' from Kurzgesagt, from the thread, Visual media for learning biology/medicine:

Over £1000 in a day. Very nice work @Joan Crawford.

I always thought of it as some side effect or other circumstance occurring that makes participants more certain what group they're in, unrelated to the outcome of interest. For example, if a patient gets a characteristic rash that is only known to happen with the active drug, they're no longer...

Muscle and cerebral oxygenation during exercise in fibromyalgia: a near-infrared spectroscopy study Taneli Lehto, Teemu Zetterman, Dominique Gagnon, Ritva Markkula, Jari Arokoski, Eija Kalso & Juha E. Peltonen [Line breaks added] Purpose We studied muscle and brain oxygenation during...

No, not that I can see.

Now published: Web | PDF Only minor formatting changes to abstract from above version.

Previous paper: Development and evaluation of blood-based prognostic biomarkers for COVID disease outcomes using EpiSwitch 3-dimensional genomic regulatory immuno-genetic profiling, 2024, Hunter et al Thread for press release about that paper: Oxford BioDynamics shares gain on Covid test...

If I understood it correctly, this study looked at absolute count of CD16+CD56+ cells at baseline in the blood, like the ME/CFS study, and found no correlation with response to daratumumab: Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory...

For this one, frequency of total NK cells wasn't different between multiple myeloma responders and nonresponders in either bone marrow or blood. What was different was higher proportion of CD16+ NK cells and lower TIM-3+ NK and HLA-DR+ NK cells in the bone marrow in responders. I'm not sure if...

It'd would be good to know how correct this is about, for example, spleen plasma cells being mostly non-specific. That's just what I remember from an intro to immunology textbook. Maybe high IGHV3-30 from the other studies might also point to overly high levels of non-specific innate-like...

Maybe, but if blood count was a good proxy for bone marrow count, I'd expect studies showing that blood NK count in multiple myeloma correlates with improvement from dara, but I haven't seen such a study. I don't think it's impossible. Maybe the body can deal with the antibodies from, say, 1000...

I think also: 1. Faulty T cells being the problem 2. Faulty NK cells being the problem 3. Some other cell that expresses CD38 being the problem. I don't think they say anything about exact levels of protective antibodies, just that they're still at protective levels at 12 months, so maybe...

The association of fatigue and pain with cognitive test performance in patients with myalgic encephalomyelitis/chronic fatigue syndrome Joukje M. Oosterman, Marieke van der Schaaf, Willemien P.E. de Kleijn, Tanja A. Kuut, Inti A. Brazil, Hans Knoop Highlights • Fatigue severity was the...

Preliminary evaluation of a cognitive rehabilitation intervention for post-COVID-19 cognitive impairment: A pilot randomized controlled trial Jacqueline H. Becker, Eric Watson, Nadia Zubair, Fernando Carnavali, Emilia Bagiella, David Reich, Juan P. Wisnivesky Background: Despite the profound...

Experiences of living with long COVID during childhood and adolescence: a qualitative study from the child’s perspective Emmy Lillieberg, Per Ertzgaard, Eva Fernlund, Karel Duchen, Patrik Rytterström & Charlotte Angelhoff Background In February 2023, the World Health Organization (WHO)...

I'm not sure. Maybe higher dose? Here's the paper you linked to: Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma, 2017 Fig 2B They used 16 mg/kg in multiple myeloma for that chart. The ME/CFS study used 1800 mg. I'm...

What I see is that recovery begins sometime after 9 months (in the 7 that have data past 9 months). Maybe one participant's NK count went back up at 10 months, but they weren't tested again until 15 months, and maybe another's count didn't go back up until 20 months, and that's when they were...

At 9 months I still see 3 participants lower than the previous point. At the next point, they all increased, but note that that point spans a very wide range spanning 6 to 12 months after the 9 month test. Also, this shows data for only 7 out of 10 participants after 9 months.

Genome-wide association study of adolescent-onset depression Abstract Adolescent depression is a heritable psychiatric condition with rising global prevalence and severe long-term outcomes, yet its biological underpinnings remain poorly understood. We conducted the first genome-wide...

Immunological and non-immunological features specific to Long-COVID: multiple overlapping aetiologies and potential biomarkers Frederique C Ponchel [Line breaks added] Abstract Long-COVID (LC) is a serious clinical condition characterised by debilitating fatigue together with a wide array of...